NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Profluent Bio

Profluent Bio

Private
Berkeley, CaliforniaHealthcare & Life Scienceshttps://www.profluent.bio/

Last Round

Series B

Nov 19, 2025

Est. Valuation

$975M

Total Funding Raised

$362M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Profluent Bio is a biotechnology company that develops artificial intelligence-based models to design and validate novel, functional proteins for human health and industrial applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Foundation

Keywords

generative AIprotein designgene editingAI drug discoveryfoundation modelfrontier AI labgenetic medicinerecombinasede novo proteinsbase editingAI biotechprotein atlasepigeneticsin silico biologybiotech platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Profluent Bio Comparables

Compare Profluent Bio with similar companies based on industry and business-model similarity.

Profluent Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Evozyne
88%
Generate Biomedicines
86%
EvolutionaryScale
85%

Profluent Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 19, 2025
Early FundingNov 19, 2025
Series BMay 22, 2024
Series AMar 21, 2024
SeedJan 26, 2023

Profluent Bio Investors

Notable investors and investment history

Profluent Bio investors
InvestorRounds
Air Street CapitalSeries B, Early Funding, Seed, Series A
Bezos ExpeditionsSeries B, Early Funding
Convergent VenturesSeed
Spark CapitalSeries B, Early Funding, Series A
AIX VenturesSeed
Insight PartnersSeries B, Early Funding, Series A, Seed
Altimeter Capital ManagementSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 23, 2026

    Grew 23% QoQ from 56 to 69 employees.

  • Apr 28, 2026

    Multi-program deal worth up to $2.25 billion for AI-designed enzymes.

Profluent Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Profluent Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Profluent Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersBerkeley, California
Employee Range69
Year Founded2022
Last FundingNov 19, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.